Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genprex, Inc. - Common Stock
(NQ:
GNPX
)
0.2750
+0.0205 (+8.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genprex, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy
August 16, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
August 16, 2022
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 15, 2022
Via
Benzinga
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
August 15, 2022
Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New...
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial to Higher Dose
August 15, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
July 13, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in June Investor Conferences
June 02, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference
May 19, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist
May 09, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update
May 05, 2022
Via
Investor Brand Network
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 03, 2022
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences
April 18, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment
March 31, 2022
Via
Investor Brand Network
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
March 31, 2022
From
Genprex, Inc.
Via
Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference
March 23, 2022
Via
Investor Brand Network
Genprex to Participate in Upcoming Investor Conference in March
March 23, 2022
From
Genprex, Inc.
Via
Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial
March 02, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences
February 09, 2022
Via
Investor Brand Network
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
February 09, 2022
From
Genprex, Inc.
Via
Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System
January 27, 2022
Via
Investor Brand Network
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
January 27, 2022
From
Genprex, Inc.
Via
Business Wire
18 Stocks Moving in Wednesday's Pre-Market Session
January 26, 2022
Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.1% to $0.23 in pre-market trading after gaining around 4% on Tuesday. Barfresh Food Group, Inc. (NASDAQ: BRFH) shares rose 31.7% to $...
Via
Benzinga
48 Biggest Movers From Yesterday
January 14, 2022
Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58...
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites
January 10, 2022
Via
Investor Brand Network
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
January 10, 2022
From
Genprex, Inc.
Via
Business Wire
50 Biggest Movers From Yesterday
January 06, 2022
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 05, 2022
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is...
Via
Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
January 05, 2022
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage...
Via
Benzinga
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
January 05, 2022
From
Genprex, Inc.
Via
Business Wire
45 Biggest Movers From Yesterday
January 05, 2022
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.